Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 1
2004 3
2005 6
2006 1
2007 3
2008 3
2009 5
2010 4
2011 5
2012 2
2013 4
2014 4
2015 6
2016 2
2017 10
2018 7
2019 10
2020 17
2021 24
2022 19
2023 21
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for zucker nash
Search for Zuiker Nash instead (1 results)
Acute flaccid myelitis: cause, diagnosis, and management.
Murphy OC, Messacar K, Benson L, Bove R, Carpenter JL, Crawford T, Dean J, DeBiasi R, Desai J, Elrick MJ, Farias-Moeller R, Gombolay GY, Greenberg B, Harmelink M, Hong S, Hopkins SE, Oleszek J, Otten C, Sadowsky CL, Schreiner TL, Thakur KT, Van Haren K, Carballo CM, Chong PF, Fall A, Gowda VK, Helfferich J, Kira R, Lim M, Lopez EL, Wells EM, Yeh EA, Pardo CA; AFM working group. Murphy OC, et al. Lancet. 2021 Jan 23;397(10271):334-346. doi: 10.1016/S0140-6736(20)32723-9. Epub 2020 Dec 23. Lancet. 2021. PMID: 33357469 Free PMC article. Review.
Outbreaks of AFM have occurred across multiple global regions since 2012, and the disease appears to be caused by non-polio enterovirus infection, posing a major public health challenge. ...
Outbreaks of AFM have occurred across multiple global regions since 2012, and the disease appears to be caused by non-polio enterovir …
Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolism.
Ferguson D, Eichler SJ, Yiew NKH, Colca JR, Cho K, Patti GJ, Shew TM, Lutkewitte AJ, Mukherjee S, McCommis KS, Niemi NM, Finck BN. Ferguson D, et al. Mol Metab. 2023 Apr;70:101694. doi: 10.1016/j.molmet.2023.101694. Epub 2023 Feb 18. Mol Metab. 2023. PMID: 36801448 Free PMC article. Clinical Trial.
OBJECTIVE: The mitochondrial pyruvate carrier (MPC) has emerged as a therapeutic target for treating insulin resistance, type 2 diabetes, and nonalcoholic steatohepatitis (NASH). We evaluated whether MPC inhibitors (MPCi) might correct impairments in branched chain amino a …
OBJECTIVE: The mitochondrial pyruvate carrier (MPC) has emerged as a therapeutic target for treating insulin resistance, type 2 diabetes, an …
Hail Mary.
Nash IS. Nash IS. JAMA Neurol. 2020 Feb 1;77(2):159. doi: 10.1001/jamaneurol.2019.3950. JAMA Neurol. 2020. PMID: 31790516 No abstract available.
Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway.
Li L, Li Q, Huang W, Han Y, Tan H, An M, Xiang Q, Zhou R, Yang L, Cheng Y. Li L, et al. Front Pharmacol. 2021 May 17;12:589273. doi: 10.3389/fphar.2021.589273. eCollection 2021. Front Pharmacol. 2021. PMID: 34093169 Free PMC article.
Recent clinical studies have found that dapagliflozin alleviates non-alcoholic fatty liver disease (NAFLD), but the specific mechanism remains to be explored. ...Dapagliflozin attenuated hepatic lipid accumulation both in vitro and in vivo. In …
Recent clinical studies have found that dapagliflozin alleviates non-alcoholic fatty liver disease (NAFLD …
Community Socioeconomic Deprivation Predicts Nonalcoholic Steatohepatitis.
Giammarino AM, Qiu H, Bulsara K, Khan S, Jiang Y, Da BL, Bernstein DE, Satapathy SK. Giammarino AM, et al. Hepatol Commun. 2022 Mar;6(3):550-560. doi: 10.1002/hep4.1831. Epub 2021 Oct 20. Hepatol Commun. 2022. PMID: 34668658 Free PMC article.
In order to determine the relationship between socioeconomic deprivation and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH), we retrospectively reviewed the electronic medical records of 1,430 patients in a large tertiary …
In order to determine the relationship between socioeconomic deprivation and nonalcoholic fatty liver disease (NAFLD)/n …
Pharmacotherapeutic Impact on Nonalcoholic Steatohepatitis Histology: A Systematic Review and Network Meta-analysis.
Kovalic AJ. Kovalic AJ. J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1057-1068. doi: 10.1016/j.jceh.2022.01.011. Epub 2022 Feb 1. J Clin Exp Hepatol. 2022. PMID: 35814516 Free PMC article.
BACKGROUND: Due to lack of targeted treatment options and inconsistent utilization of histologic endpoints among clinical trials, identifying efficacious pharmacotherapies for nonalcoholic steatohepatitis [NASH] has proven challenging. METHODS: A thorough systematic review …
BACKGROUND: Due to lack of targeted treatment options and inconsistent utilization of histologic endpoints among clinical trials, identifyin …
Nonalcoholic Steatohepatitis: A Search for Factual Animal Models.
Sanches SC, Ramalho LN, Augusto MJ, da Silva DM, Ramalho FS. Sanches SC, et al. Biomed Res Int. 2015;2015:574832. doi: 10.1155/2015/574832. Epub 2015 May 3. Biomed Res Int. 2015. PMID: 26064924 Free PMC article. Review.
Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis, which occurs in the absence of alcohol abuse. NAFLD can evolve into progressive liver injury and fibrosis in the form of nonalcoholic steatohepatitis (NASH). ...
Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis, which occurs in the absence of alcohol …
137 results